A Randomized, Double Blind, Placebo Controlled, Three- Period Crossover Study Comparing the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo on QT Intervals in Healthy Adults.

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Three- Period Crossover Study Comparing the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo on QT Intervals in Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs Dihydroergotamine mesilate (Primary) ; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Cluster headache; Community-acquired pneumonia; Intra-abdominal infections; Migraine; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Adverse reactions; Registrational
  • Sponsors MAP Pharmaceuticals
  • Most Recent Events

    • 26 Jun 2011 Results presented at the 15th Congress of the International Headache Society.
    • 05 Jun 2011 Results presented at the 53rd Annual Scientific Meeting of the American Headache Society.
    • 10 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top